Literature DB >> 16735798

Lysine as a critical amino acid for IgE binding in Phl p 5b C terminus.

Kirsten Gehlhar1, Kanagalaghata R Rajashankar, Eckhard Hofmann, Christian Betzel, Wolfgang Weber, Sandra Werner, Albrecht Bufe.   

Abstract

BACKGROUND: Allergens induce the formation of specific immunoglobulin (Ig)E and harbor at least two IgE-binding regions (epitopes) to facilitate crosslinking of basophilic or mast-cell-bound specific IgE antibodies. Studies mapping linear epitopes have shown that these regions often contain charged or hydrophobic amino acids. Nevertheless, these studies are hampered by limited significance due to the often conformational nature of IgE epitopes. This prompted us to study the role of lysines in the context of an intact 3-dimensional model.
METHODS: Major allergen Phl p 5b from timothy grass bears 12 lysines in its C-terminal half. Using site-directed mutagenesis, we substituted all 10 surface-exposed lysines by alanines.
RESULTS: Although structural integrity of the lysine-deficient mutant was not altered, IgE-binding capacity measured by ELISA inhibition tests and crosslinking activity in ex vivo basophil stimulation and in vivo skin prick tests were significantly diminished. Interestingly, binding of specific IgG antibodies was considerably less reduced by loss of lysines.
CONCLUSION: Lysine is an important amino acid for IgE binding in more than one epitope of major grass pollen allergen Phl p 5b C terminus. Allergenicity, but not IgG binding of the molecule, is substantially diminished by single amino acid substitutions without structural integrity being hampered. Copyright 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16735798     DOI: 10.1159/000093706

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  7 in total

1.  Close-up of the immunogenic α1,3-galactose epitope as defined by a monoclonal chimeric immunoglobulin E and human serum using saturation transfer difference (STD) NMR.

Authors:  Melanie Plum; Yvonne Michel; Katharina Wallach; Tim Raiber; Simon Blank; Frank I Bantleon; Andrea Diethers; Kerstin Greunke; Ingke Braren; Thomas Hackl; Bernd Meyer; Edzard Spillner
Journal:  J Biol Chem       Date:  2011-10-11       Impact factor: 5.157

2.  Multiple independent IgE epitopes on the highly allergenic grass pollen allergen Phl p 5.

Authors:  M Levin; S Rotthus; S Wendel; N Najafi; E Källström; M Focke-Tejkl; R Valenta; S Flicker; M Ohlin
Journal:  Clin Exp Allergy       Date:  2014-11       Impact factor: 5.018

3.  Comprehensive 3D-modeling of allergenic proteins and amino acid composition of potential conformational IgE epitopes.

Authors:  Numan Oezguen; Bin Zhou; Surendra S Negi; Ovidiu Ivanciuc; Catherine H Schein; Gilles Labesse; Werner Braun
Journal:  Mol Immunol       Date:  2008-07-14       Impact factor: 4.407

4.  Mechanisms of allergen-antibody interaction of cockroach allergen Bla g 2 with monoclonal antibodies that inhibit IgE antibody binding.

Authors:  Jill Glesner; Sabina Wünschmann; Mi Li; Alla Gustchina; Alexander Wlodawer; Martin Himly; Martin D Chapman; Anna Pomés
Journal:  PLoS One       Date:  2011-07-15       Impact factor: 3.240

5.  Longitudinal Metabolomic Analysis Reveals Gut Microbial-Derived Metabolites Related to Formula Feeding and Milk Sensitization Development in Infancy.

Authors:  Ching-Min Tang; Gigin Lin; Meng-Han Chiang; Kuo-Wei Yeh; Jing-Long Huang; Kuan-Wen Su; Ming-Han Tsai; Man-Chin Hua; Sui-Ling Liao; Shen-Hao Lai; Chih-Yung Chiu
Journal:  Metabolites       Date:  2022-01-28

6.  Specific Immunotherapy in a Murine Model of Grass Pollen (Phl p5b)-Induced Airway Inflammation.

Authors:  Matthias Stiehm; Marcus Peters
Journal:  Front Allergy       Date:  2021-12-16

7.  A naturally occurring hypoallergenic variant of vespid Antigen 5 from Polybia scutellaris venom as a candidate for allergen-specific immunotherapy.

Authors:  Sabrina E Vinzón; Cristina Marino-Buslje; Elena Rivera; Mirtha Biscoglio de Jiménez Bonino
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.